GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).
    American Society of Clinical Oncology (ASCO) ; 2013
    In:  Journal of Clinical Oncology Vol. 31, No. 4_suppl ( 2013-02-01), p. LBA445-LBA445
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 4_suppl ( 2013-02-01), p. LBA445-LBA445
    Abstract: LBA445 Background: The literature reports that adding biologics to chemotherapy (ctx) may increase the incidence of clinically significant neutropenia. This trial was conducted to evaluate the efficacy of PEG in reducing the incidence of febrile neutropenia (FN) in pts with locally advanced (LA) or metastatic (m)CRC receiving first-line treatment with either FOLFOX/B or FOLFIRI/B. Methods: Key eligibility: ≥ 18 years old; measurable, nonresectable CRC per RECIST 1.1. Pts were randomly assigned 1:1 to either placebo or 6 mg PEG ~24 h after ctx/B. The study treatment period included four Q2W cycles, but pts could continue their assigned regimen until progression. Pts were stratified by region (North America vs rest of world), stage (LA vs mCRC), and ctx (FOLFOX vs FOLFIRI). Estimated sample size (N = 800) was based on the expected incidence of grade 3/4 FN (primary endpoint) across the first 4 cycles of ctx/B, powered for PEG superiority over placebo. Other endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: 845 pts were randomized (Nov 2009 to Jan 2012) and received study treatment; 783 pts completed 4 cycles of ctx/B. Median age was 61 years; 512 (61%) pts were male; 819 (97%) had mCRC; 414 (49%) received FOLFOX, and 431 (51%) received FOLFIRI. Grade 3/4 FN (first 4 cycles) for placebo vs PEG was 5.7% vs 2.4%; OR 0.41; p = 0.014. A similar incidence of other ≥ grade 3 adverse events was seen in both arms (28% placebo; 27% PEG). See Table for additional results. Conclusions: PEG significantly reduced the incidence of grade 3/4 FN in this pt population receiving standard ctx/B for CRC. Follow-up is ongoing. Clinical trial information: NCT00911170. [Table: see text]
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/jco.2013.31.4_suppl.lba445
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2013
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Multidisciplinary Treatment Of Malignant Pleural And Peritoneal Mesothelioma In Klaipeda University Hospital. Case Report
    Association of Lithuanian Serials (Publications) ; 2016
    In:  Sveikatos mokslai Vol. 26, No. 5 ( 2016-12-22), p. 40-47
    Details
    In: Sveikatos mokslai, Association of Lithuanian Serials (Publications), Vol. 26, No. 5 ( 2016-12-22), p. 40-47
    Abstract: Malignant mesothelioma is an aggressive tumor of serosal surfaces, such as the pleura, the peritoneum, the pericardium and the tunica vaginalis. There is a substantial interest in this disease by part of medical community and the general public because millions of people have been exposed to asbestos fibers, and many articles about the dangers of asbestos had appeared in the press. 80 percent of patients with pleural malignant mesothelioma are male, commonly present with a pleural effusion, associated with breathlessness and often accompanied by chest-wall pain (more than 60 percent of patients). The main cause of malignant mesothelioma is exposure to asbestos – the carcinogen associated with malignant mesothelioma. Indeed, malignant mesothelioma was rare before the widespread use of asbestos, and increasing incidence worldwide is expected to peak in 5 to 10 years. The pathologic diagnostic of malignant mesothelioma is very difficult even with pathology experts in mesothelioma. Accurate and rapid diagnosis of malignant mesothelioma is important for therapeutic reasons. The most frequent diagnostic problem is the differentiation of malignant mesothelioma and adenocarcinoma – a distinction that is particularly difficult to make when the tumor has invaded the pleura. For many years surgery has proved to be most useful for palliation – for example, for local control of recurrent effusions. Debulking surgery is used in some centers until now. Systemic chemotherapy, cytoreductive surgery, HYPEC and multidisciplinary team discussion can help to cure or extend survival of patients. The case report showed successful multidisciplinary approach treatment for young man with malignant pleural and peritoneal mesothelioma.
    Type of Medium: Online Resource
    ISSN: 1392-6373
    URL: Article
    DOI: 10.5200/sm-hs.2016.070
    Language: Unknown
    Publisher: Association of Lithuanian Serials (Publications)
    Publication Date: 2016
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Concomitant Bioradiotherapy of Locally Advanced Head and Neck Cancer at the Klaipeda University Hospital
    Association of Lithuanian Serials (Publications) ; 2013
    In:  Sveikatos mokslai Vol. 23, No. 3 ( 2013-09-15), p. 24-26
    Details
    In: Sveikatos mokslai, Association of Lithuanian Serials (Publications), Vol. 23, No. 3 ( 2013-09-15), p. 24-26
    Type of Medium: Online Resource
    ISSN: 1392-6373
    URL: Article
    DOI: 10.5200/sm-hs.2013.069
    Language: English
    Publisher: Association of Lithuanian Serials (Publications)
    Publication Date: 2013
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    EGFR Mutations Status For Non-Small-Cell Lung Cancer Patients
    Association of Lithuanian Serials (Publications) ; 2016
    In:  Sveikatos mokslai Vol. 26, No. 5 ( 2016-12-22), p. 36-39
    Details
    In: Sveikatos mokslai, Association of Lithuanian Serials (Publications), Vol. 26, No. 5 ( 2016-12-22), p. 36-39
    Abstract: With the advent of the molecular-targeted therapy, rapid progress has been made in the treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). EGFR mutations detection in tumor is important to determine an appropriate treatment of EGFR TK inhibitors. We investigated EGFR mutation status for patients with non-small cells lung carcinoma (NSCLC) patients’ tumorous cells from FFPE material in Klaipeda University Hospital, Lithuania (mutation test for the qualitative detection and identification of mutations in exons 18, 19, 20 and 21 of the EGFR gene) and T790M mutation in cfDNA (Liquid biopsy). Mutations of EGFR from FFPE were detected in 24 of the 119 patients (20%). EGFR mutations were more frequently found in women (13 of 36, 36%). cfDNA (Liquid biopsy) testing results show one of the patients had EGFR 20 exon T790M mutation detected which is resistance determining factor for the first and second generation EGFR TK Inhibitors treatment and a predicting marker for the third generation EGFR TK Inhibitors treatment.
    Type of Medium: Online Resource
    ISSN: 1392-6373
    URL: Article
    DOI: 10.5200/sm-hs.2016.069
    Language: Unknown
    Publisher: Association of Lithuanian Serials (Publications)
    Publication Date: 2016
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    POOPERACINĖS SEROMOS IR ŽAIZDŲ PRIEŽIŪRA PO KRŪTIES OPERACIJŲ
    Association of Lithuanian Serials (Publications) ; 2017
    In:  Visuomenės sveikata Vol. 27, No. 5 ( 2017-12-20), p. 101-105
    Details
    In: Visuomenės sveikata, Association of Lithuanian Serials (Publications), Vol. 27, No. 5 ( 2017-12-20), p. 101-105
    Abstract: Krūties vėžys – dažniausia onkologinė moterų liga Lietuvoje ir pasaulyje. Kasmet atliekama daugybė krūtų operacijų, kurios pasižymi specifiškomis komplikacijomis. Dažniausia iš jų seroma, pasitaikanti 3 – 85% atvejų. Nekomplikuotų krūties ir pažasties sričių seromų evakavimo procedūros kai kurių šalių ligoninėse patikėtos krūtų priežiūros slaugytojoms.
    Type of Medium: Online Resource
    ISSN: 2335-867X
    URL: Article
    DOI: 10.5200/sm-hs.2017.086
    Language: Unknown
    Publisher: Association of Lithuanian Serials (Publications)
    Publication Date: 2017
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Safety And Toxicity Combining Radiation Therapy With A Biologic Therapy In Locally Advanced Head And Neck Squamous Cell Cancer At The Klaipeda University Hospital Clinical Practice
    Association of Lithuanian Serials (Publications) ; 2016
    In:  Sveikatos mokslai Vol. 26, No. 5 ( 2016-12-22), p. 93-96
    Details
    In: Sveikatos mokslai, Association of Lithuanian Serials (Publications), Vol. 26, No. 5 ( 2016-12-22), p. 93-96
    Abstract: We retrospectively reviewed head and neck cancer cases, treated cetuximab concomitantly with radiotherapy in Klaipeda University Hospital. Comparison of acute side efects of bioradiotherapy and survival analysis.
    Type of Medium: Online Resource
    ISSN: 1392-6373
    URL: Article
    DOI: 10.5200/sm-hs.2016.079
    Language: Unknown
    Publisher: Association of Lithuanian Serials (Publications)
    Publication Date: 2016
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    METASTAZAVUSIOS MELANOMOS GYDYMAS BRAF INHIBITORIAIS KLAIPĖDOS UNIVERSITETINĖJE LIGONINĖJE. NEPAGEIDAUJAMI REIŠKINIAI
    Association of Lithuanian Serials (Publications) ; 2014
    In:  Sveikatos mokslai Vol. 24, No. 5 ( 2014-02-20), p. 39-42
    Details
    In: Sveikatos mokslai, Association of Lithuanian Serials (Publications), Vol. 24, No. 5 ( 2014-02-20), p. 39-42
    Abstract: Melanoma - piktybinis odos navikas, kilęs iš melanocitų, melaniną produkuojančių ląstelių. Piktybinės melanomos vystymesi labiausiai žinomi du pagrindiniai RAS/RAF/MEK/ERK (MAPK) ir PI3K/ PTEN/AKT (AKT) signalo perdavimo keliai, kurie nenutrūkstamai aktyvuojami įvykus ląstelių genetiniams pokyčiams. Dėl to sutrinka normali ląstelių proliferacija, diferencijacija, angiogenezė, vystosi melanoma. Siekiant surasti geriausią melanomos gydymo būdą, būtina suprasti melanomos biologiją, signalo perdavimo mechanizmus. Aktyvuojančios BRAF geno mutacijos ir intraląstelinių signalo kelių, reguliuojančių ląstelės augimo, dauginimosi, mirties mechanizmus, atradimas pakeitė melanomos biologijos suvokimą ir atvėrė plačias galimybės ieškoti taikinių terapijos prieš BRAF bei kitus onkogenus. Klaipėdos universitetinėje ligoninėje 2012-2014 m. pacientai, sergantys metastazavusia melanoma, buvo gydyti BRAF inhibitoriu vemurafenibu, o nuo 2013 m. vykdyta išplėstinė medikamentų prieinamumo programa: dabrafenibas bei BRAF ir MEK inhibitorių kombinacija (dabrafenibas su trametinibu).
    Type of Medium: Online Resource
    ISSN: 1392-6373
    URL: Article
    DOI: 10.5200/sm-hs.2014.091
    Language: Unknown
    Publisher: Association of Lithuanian Serials (Publications)
    Publication Date: 2014
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
    Ovid Technologies (Wolters Kluwer Health) ; 2020
    In:  Melanoma Research Vol. 30, No. 3 ( 2020-06), p. 261-267
    Details
    In: Melanoma Research, Ovid Technologies (Wolters Kluwer Health), Vol. 30, No. 3 ( 2020-06), p. 261-267
    Abstract: In clinical trials, dabrafenib plus trametinib improved overall survival (OS) compared with single-agent BRAF inhibitors (BRAFi) in patients with BRAF V600-mutant unresectable or metastatic melanoma. We investigated dabrafenib plus trametinib therapy in a compassionate-use setting [Named Patient Program (NPP); DESCRIBE II]. A retrospective chart review of patients with BRAF V600-mutated unresectable stage III/IV melanoma receiving dabrafenib plus trametinib as compassionate use was conducted. Treatment patterns and duration, clinical outcomes, and tolerability were evaluated. Of 271 patients, 92.6% had stage IV melanoma, including 36.5% with brain metastases. Overall, 162 patients (59.8%) were BRAFi naive and 171 (63.1%) received first-line dabrafenib plus trametinib. Among BRAFi-naive patients, the overall response rate (ORR) was 67.3%, median OS (mOS) was 20.0 months, and median progression-free survival (mPFS) was 7.5 months. In BRAFi-naive patients with known brain metastases ( n = 62), ORR was 61.3%, mOS was 15.5 months, and mPFS was 6.2 months. Eighty-four patients received BRAFi monotherapy for 〉 30 days and switched to dabrafenib plus trametinib prior to progression. Of these 84 patients, 63 had known disease status at the time of switch, and 22 improved with the combination therapy. No new safety signals were identified, and dabrafenib plus trametinib was well tolerated. Dabrafenib plus trametinib showed substantial clinical activity in NPP patients with BRAF V600-mutated unresectable or metastatic melanoma. Analysis of treatment patterns demonstrated the effectiveness of the combination in patients with brain metastases and across lines of therapy with a well tolerated and manageable safety profile.
    Type of Medium: Online Resource
    ISSN: 0960-8931
    URL: Article
    DOI: 10.1097/CMR.0000000000000654
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2020
    detail.hit.zdb_id: 1095779-0
    detail.hit.zdb_id: 2030780-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    NAUJA PLAUKŲ IŠSAUGOJIMO GALIMYBĖ TAIKANT CHEMOTERAPIJĄ
    Association of Lithuanian Serials (Publications) ; 2019
    In:  Visuomenės sveikata Vol. 28, No. 7 ( 2019-01-24), p. 50-53
    Details
    In: Visuomenės sveikata, Association of Lithuanian Serials (Publications), Vol. 28, No. 7 ( 2019-01-24), p. 50-53
    Abstract: Įvadas. Krūties vėžys – dažniausia moterų onkolo­ginė liga. Sergančiosioms taikomas kompleksinis gy­dymas, kurio metu naudojami tokie gydymo metodai kaip chirurginis, spindulinė terapija ir chemoterapija. Plačiausias gydymo metodas – chemoterapija. Jos metu dažnai pasireiškia nepageidaujami poveikiai, tokie kaip plaukų slinkimas. Tyrimo tikslas – išanalizuoti plaukų išsaugojimo ga­limybes taikant chemoterapinį gydymą moterims, sergančioms krūties vėžiu. Tyrimo metodika. Klaipėdos universitetinėje ligoni­nėje atliktas kiekybinis tyrimas: anoniminė anketinė apklausa. Tyrime dalyvavo 67 krūties vėžiu sergan­čios pacientės. Atlikta statistinė duomenų analizė, naudojant SPSS ir MS EXCEL 2007 programas. Rezultatai. Tyrimas atskleidė, jog 50 moterų (76,1 proc.) yra svarbu arba labai svarbu išsaugoti plau­kus. Tyrinėjant plaukų slinkimą chemoterapijos metu, naudojant galvos odos šaldymo aparatą pastebime, jog po IV kurso 68,7 proc. moterų patyrė neakivaizdų slinkimą, kuris nepastebimas iš arti. Taip pat 38 mo­terys (56,7 proc.) teigia, jog yra patenkintos galvos šaldymo aparato rezultatais. Išvados. Tvirtai galima teigti, jog galvos odos šal­dymo procedūra yra efektyvi. 68,7% respondenčių teigia, jog yra patenkintos procedūros rezultatais, dėl ko nereikėjo naudoti galvos apdangalų ar perukų.
    Type of Medium: Online Resource
    ISSN: 2335-867X
    URL: Article
    DOI: 10.5200/sm-hs.2018.090
    Language: Unknown
    Publisher: Association of Lithuanian Serials (Publications)
    Publication Date: 2019
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    ATVEJO VADYBOS TAIKYMAS KLAIPĖDOS UNIVERSITETINĖJE LIGONINĖJE KURIANT PERSONALIZUOTĄ ONKOLOGINIŲ LIGONIŲ SVEIKATOS PRIEŽIŪRĄ
    Association of Lithuanian Serials (Publications) ; 2019
    In:  Visuomenės sveikata Vol. 28, No. 7 ( 2019-01-24), p. 115-120
    Details
    In: Visuomenės sveikata, Association of Lithuanian Serials (Publications), Vol. 28, No. 7 ( 2019-01-24), p. 115-120
    Abstract: Onkologinių ligų sveikatos priežiūra reikalauja indi­vidualios vadybinės prieigos dėl šios ligos sudėtin­gumo ir didelių gydymo kaštų. Siekiant efektyviai ir veiksmingai suvaldyti navikinių ligų keliamus iššū­kius, personalizuotos (į asmenį orientuotos) pagalbos taikymas šiandien laikomas palankiausiai vertinama alternatyva, aukščiausios paslaugų kokybės ir paci­entų pasitenkinimo paslaugomis garantas. Pabrėž­tina, kad personalizuota onkologinių ligonių sveikatos priežiūra, paremta holistiniu požiūriu, skatina įgyven­dinti rimtus pokyčius organizaciniu lygmeniu. Kaip pasekmė, rutininėje gydymo įstaigų veiklos prakti­koje vis dažniau pradedama taikyti atvejo vadyba. Tyrimo tikslas: mokslinės literatūros pagrindu įver­tinti atvejo vadybos taikymo ypatumus klinikinėje praktikoje bei pristatyti Klaipėdos universitetinėje ligoninėje taikomą atvejo vadybos modelį.
    Type of Medium: Online Resource
    ISSN: 2335-867X
    URL: Article
    DOI: 10.5200/sm-hs.2018.102
    Language: Unknown
    Publisher: Association of Lithuanian Serials (Publications)
    Publication Date: 2019
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...